---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-027197"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2026-06-04T11:30:38+00:00"
generated_at: "2026-06-04T11:35:25.115347+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Abeona holds constructive Pre-IND meeting with FDA for ABO-701; IND target 2027

## Summary
- Pre-IND meeting with FDA held June 3, 2026 for ABO-701, a T-cell therapy targeting PSMA for prostate cancer.
- Company characterizes meeting as constructive; official FDA minutes not yet received.
- IND submission for ABO-701 remains targeted for 2027, consistent with prior guidance.
- No assurance that FDA will accept IND or that additional studies won't be required.
- Development plans subject to revision based on FDA feedback, preclinical results, and manufacturing.

## SEC filing metadata
- accession: 0001493152-26-027197
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2026-06-04T11:30:38+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315226027197/0001493152-26-027197-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315226027197/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-027197
- JSON: https://secwatch.observer/filing/0001493152-26-027197.json
- Plain text: https://secwatch.observer/filing/0001493152-26-027197.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.